My thoughts exactly as it must not be any coincidence PFM also buys out Epiontis, both were working on Biomarkers with Peregrine and that is where the beginning of my concerns were to point out that any patents filed based upon PS Targeting reached, new knowledge into Biomarkers which were not known before and impossible to be known unless one see the protein pathways changed AFTER PS Targeting and only that evidence allowed PFM or Epiontis to conclude new information never known before .....well, not even any patents must have rights rolled back to Peregrine but how about any of this info used to design or modify trials based on this information (Biomarkers...etc) must be known to Peregrine Pharmaceuticals and with King and men departed can we trust that current BODs will comply with their Firuciary Duties ?
_______
After reading this patent more closely....this "upstream" looks like it could be referring to Phosphatidylserine and now more interesting is the Epiontis collaboration with Peregrine and Turbachova laboratory
Market Data 
Markets 
AI
